Retinal disease pharmaceutical sales will reach $11.98bn in 2017, a new visiongain study predicts

15 August 2017
Pharma

A new report by visiongain forecasts the overall world market for treating age-related macular degeneration (AMD or ARMD), diabetic retinopathy (DR) and other disorders of the retina will reach $11.98bn in 2017. That revenue forecast and others appear in Macular Degeneration (AMD) & Diabetic Retinopathy (DR) Market Forecast 2017-2027: Outlook & Analysis for Ophthalmic Drugs for Other Retinal Diseases Including Age-Related Macular Degeneration (ARMD), Dry AMD, Wet AMD, Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO) & Geographic Atrophy (GA).

Age-related macular degeneration (AMD) and other retinal diseases market is growing rapidly in pharmaceutical industry worth multi-billion dollar sector. That updated report provides the detailed analysis and opportunities in wet AMD, dry AMD and diabetic retinopathy (DR) sector. Many pharmaceutical companies are aiming to develop more effective drugs with different mechanism of action to treat wet AMD. At present there are no drugs in the market for dry AMD, although dry age-related macular degeneration (dAMD) is more common than wet AMD (wAMD). Currently, there are many drugs in pipeline to treat dry AMD. The breakthrough in dry AMD sector for drug to get approved is expected to happen in next 5 years, visiongain estimates. The report includes analysis and revenue forecasting for top 4 drugs in wet AMD drug market. In 2015, Eylea became number one drug in retinal diseases market leaving behind Lucentis.

There are unmet needs remaining in retinal diseases sector and pharmaceutical companies are aiming to meet these needs within the next ten years. Companies seek to improve upon the standard of care (SOC) treatment for wAMD, whilst developing new therapies for dry AMD and other retinal diseases such as diabetic retinopathy (DR) and retinal vein occlusion (RVO). The retinal disease overall market is expected to keep growing for the next 10 years as current promising pipeline candidates attain approvals. The Macular Degeneration (AMD), Diabetic Retinopathy (DR) and Other Retinal Diseases: World Drug Industry and Market Forecast 2017-2027 provides an analysis of this fast-growing market in 2017, as well as forecasting the prospects for revenue growth over the period 2017-2027.

Visiongain’s lead pharmaceutical industry analyst for this report said: “The lead analyst for this report said: “The AMD and other retinal diseases market is dominated by Lucentis and Eylea, which collectively represented 80.2% of revenues for the base year. Use of both Lucentis and Eylea will rapidly spread into other retinal disease indications, providing the main driver for the market in this period.
In the second half of the forecast period, growth in the wet AMD segment will increasingly be driven by uptake of new products, including new combination regimens based on blocking of multiple pathways. However, the segment is mature relative to other retinal disease markets, and Visiongain believes that growth rates will be moderate, as an increasing proportion of the patient population is addressed by new treatments””

That updated report shows revenue forecasts to 2027 at overall world market, disease submarket, product (brand) and national level. First it gives revenue predictions to 2027 for four therapeutic submarkets at world level:

• Wet age-related macular degeneration (wAMD)
• Dry AMD (dAMD)
• Diabetic retinopathy (DR)
• Other retinal diseases (grouped forecast).

That study then predicts revenues of four prominent drugs to 2027: Lucentis, Eylea, Avastin and Visudyne.

Research, data and analyses cover activities of Roche, Novartis, Bayer, Regeneron, Allergan, Valeant and other developers, manufacturers and marketers of ophthalmic pharmaceuticals. Analyses cover leaders and other organisations for retinal medicines.

That new study also discusses R&D and commercial news and predicts revenues to 2027 in 11 leading national markets. The work analyses the United States (US), Western Europe (Italy, Spain, Germany, the UK and France), Japan and BRIC countries (Brazil, Russia, India and China).

Macular Degeneration (AMD) & Diabetic Retinopathy (DR) Market Forecast 2017-2027: Outlook & Analysis for Ophthalmic Drugs for Other Retinal Diseases Including Age-Related Macular Degeneration (ARMD), Dry AMD, Wet AMD, Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO) & Geographic Atrophy (GA) adds to visiongain’s analyses on industries and markets in healthcare. Together those studies cover pharmaceuticals, diagnostics, medical devices, outsourced services and biotechnologies.

Recent News

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

“Global Ophthalmic Equipment market set to grow to $75bn by 2024” says new Visiongain report

here is a growing demand for ophthalmic equipment such as vision care products and ophthalmology surgical devices, mainly due to the increasing incidence of myopia across the world.

03 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever